Lite Strategy, Inc. LITS
Biotechnology: Pharmaceutical Preparations · IPO 2003 · data as of November 13, 2026
Lite Strategy, Inc. (LITS) is a healthcare company listed in the US with a market value of about $25M. In fiscal year 2026 it had revenue of $267000 and net income of -$71M, a net margin of -26647.9%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -62% a year, a 5-year average ROIC of -88%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Lite Strategy
Lite Strategy is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2003. Revenue went from $23M in 2017 to $267000 in 2026, a decline of about 39.1% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 419% over three years (dilution for shareholders). It spends 46% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $267000 | $0 | $65M | $49M | $41M | $35M | $28M | $5M | $2M | $23M |
| Net income | -$71M | -$16M | $18M | -$32M | -$54M | -$41M | -$47M | -$17M | -$40M | $3M |
| Free cash flow | — | -$21M | -$50M | -$53M | -$49M | -$33M | $33M | -$30M | — | $3M |
| EPS (diluted) | $-2.06 | $-2.39 | $2.67 | $-4.78 | $-9.99 | $-12.00 | $-10.40 | $-15.00 | $-19.40 | $1.40 |
| Net margin | -26647.9% | — | 27.6% | -65.5% | -132.7% | -117.8% | -170.0% | -342.2% | -2470.3% | 11.5% |
| ROIC | -159.9% | -103.1% | 44.0% | -98.4% | -121.6% | -82.6% | -26.3% | -76.2% | -44.8% | 4.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Lite Strategy stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Lite Strategy pay a dividend?
Not currently.
Is Lite Strategy a good stock to buy?
We do not give buy or sell advice. Lite Strategy scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.